Medical and Diagnostic Laboratories (U.S.) — An Investor's Primer

NAICS 2022 code 6215. A short, general-audience rollup for both public-market and private investors. (NAICS = North American Industry Classification System, the U.S. government's standard for grouping businesses.) This is an industry group — a four-digit level — that sits one rung above the outpatient-diagnostics industry most people picture: the freestanding labs that analyze your blood and tissue, and the centers that scan the inside of your body.

1. Overview

NAICS 6215 covers the freestanding, outpatient diagnostic layer of American medicine: businesses that turn a specimen or a signal into a result a physician can act on, without treating the patient themselves. A lab analyzes a physical sample — blood, urine, a tissue biopsy, a cheek swab. An imaging center produces a picture of your insides — an MRI, CT scan, ultrasound, X-ray, or mammogram — for a radiologist to read.[1]

For an investor, this is a defensive, demographically favored, price-taking industry: demand is recurring (people get sick regardless of the economy), the aging of the population is a durable tailwind, and the operators rarely set their own prices — government fee schedules and insurers do.

2. What's inside — and why this level equals its one child

The four-digit group 6215 contains exactly one five-digit child industry:

• 62151 — Medical and Diagnostic Laboratories.

Because there is only one child, NAICS 6215 and NAICS 62151 are, for practical purposes, the same industry — every dollar, firm, establishment, and employee at this level is the same dollar, firm, establishment, and employee at 62151. The government keeps two code levels here as a structural formality, not because they describe different things.

The substance lives one level down, where 62151 splits into two genuinely different businesses:

• 621511 — Medical Laboratories — independent labs running blood chemistry, pathology, and increasingly genomic and molecular tests (~69% of the level's revenue).[3]
• 621512 — Diagnostic Imaging Centers — standalone MRI, CT, X-ray, ultrasound, and PET facilities (~31%).[4]

This page is deliberately short. For the full treatment — the lab-versus-imaging contrast that is the whole point of the rollup, the company-by-company investable map, and the detailed economics — read the 62151 primer. What follows is only this level's own ground-truth figures and a synthesis of where value sits.

3. How big it is

Our ground-truth federal statistics for NAICS 6215. Years differ by source (revenue and concentration from the 2022 Economic Census; counts and payroll from 2023 County Business Patterns) and should not be blended into a single-period estimate. These are identical to the 62151 figures — as expected for a single-child level.

Concentration is deceptively moderate. The top 4 firms hold 24.9% of revenue, the top 8 29.9%, the top 20 38.3%, and the top 50 49.6% — so half of all revenue sits outside the 50 biggest companies.[2] The level's Herfindahl-Hirschman Index (HHI, a standard concentration gauge) is suppressed in the federal data, so we neither state nor estimate it. That middling blended figure hides two opposite structures underneath: a concentrated lab tier (top-4 ≈ 36%) welded to a fragmented imaging tier (top-4 ≈ 12.9%).[3][4] The group looks moderately consolidated; neither of its grandchild industries actually is.

Undercount caveat — important. The $81.1B is real but partial. By design: NAICS 6215 excludes labs and imaging performed inside hospitals (NAICS 622) and inside physician offices (NAICS 6211), which is where the majority of U.S. testing and scanning actually happens — so total U.S. diagnostics across all settings runs into the hundreds of billions, with clinical-lab testing alone estimated around $80–90B+ and hospital labs more than half of that.[11] By survey method: County Business Patterns excludes the self-employed, non-employer businesses, and most government workers, and the Economic Census targets paid-employee establishments and generally excludes government-owned ones.[10] These figures accurately size the employer-based, freestanding diagnostics economy — not total U.S. diagnostics — and under-represent very small owner-operated practices and public/VA/academic facilities. Our data contain no volume, utilization, payer-mix, or margin figures for the level.

4. The investable universe — where value concentrates

The single most important fact for a stock investor: the public-market opportunity is almost entirely on the lab side, not the imaging side. Labs are the larger and far more investable half, because imaging has been absorbed by private equity. Tickers and figures are reserved to this section and Section 10.

• Labs — genuine public depth. Two national pure-play giants anchor the segment, Quest Diagnostics (NYSE: DGX) and Labcorp (NYSE: LH), behind which sits a real cohort of faster-growing molecular/genomic testers (Exact Sciences, Natera, Guardant Health, NeoGenomics, Veracyte, Fulgent Genetics, plus CareDx and Myriad Genetics).[5][6][8]
• Imaging — thin public, deep private. The public menu is essentially RadNet (Nasdaq: RDNT), newly public Lumexa Imaging (Nasdaq: LMRI), and micro-cap Fonar (Nasdaq: FONR); the industry actually lives in private-equity chains and hospital joint ventures.[4][7]

The synthesis: if you want the level in one trade, you are really buying the lab majors. See the 62151 primer for the full company-by-company map.

5. How the money works

Both halves of the level are high-fixed-cost, high-volume, price-taking businesses that earn the spread between what a payer reimburses per test or scan and the marginal cost of producing it. The master lever in both is utilization — keeping expensive equipment and specialized staff busy — because once the fixed base is built, incremental volume is highly profitable:

Revenue ≈ volume × realized reimbursement per unit.

Prices are largely administered. Labs are paid off Medicare's CLFS (Clinical Laboratory Fee Schedule), pegged under PAMA (Protecting Access to Medicare Act of 2014) to the median price private insurers pay; imaging is paid off Medicare's MPFS (Physician Fee Schedule), whose conversion factor has eroded roughly 10% over a decade.[3][4] The two diverge mainly on capital intensity — a single MRI or PET/CT scanner costs low millions, so imaging is more debt-financed and more leverage-exposed than labs. Our federal data include no level-wide margin, utilization, or reimbursement figures, so none are asserted here.

6. What drives demand

The level is pulled by a handful of durable forces, detailed in the 62151 primer:

• Aging demographics — adults 65+ reached 61.2 million (18.0% of the population) in 2024 and are the heaviest users of both testing and imaging; the most durable tailwind.[14]
• Chronic disease — diabetes, cardiovascular disease, and cancer generate recurring tests and scans, not one-offs.[3][4]
• Early detection and precision medicine — genomic profiling, hereditary and prenatal testing, and broadening imaging-screening guidelines are the fastest-growing, highest-priced categories.[3][4]
• Site-of-service migration — because an identical test or scan costs far less outside a hospital, insurers and employers steer patients to freestanding sites.[4]

The common caution: diagnostics is defensive but not perfectly recession-proof — volume softens when patients defer care, and was distorted by the COVID-19 surge and its normalization.

7. Regulation

Regulation across the level is both a moat (barriers to entry) and a risk (prices and rules set by others). Reimbursement is administered by CMS (Centers for Medicare & Medicaid Services) via the CLFS for labs and the MPFS for imaging; fraud-and-abuse law (the Anti-Kickback Statute, the Stark Law on physician self-referral, the False Claims Act) governs billing and referrals; and HIPAA (Health Insurance Portability and Accountability Act) protects the large volumes of patient data both hold.[3][4][12][13] The regime specifics differ by grandchild — CLIA licensure and the Laboratory-Developed Test rules on the lab side; IDTF enrollment, MQSA mammography certification, and Certificate-of-Need on the imaging side — and are covered in the 62151 primer.

8. Consolidation

Consolidation is the defining trend across the whole level — running on two clocks. Labs are consolidating from an already-concentrated top: the two majors keep buying regional labs, molecular capabilities, and hospital outreach labs, adding to a segment where the top four already hold ~36%.[3] Imaging is consolidating from a fragmented base — the roll-up story here is younger and larger, led by private equity (PE-employed radiologists jumped from ~1% to ~12% of the profession in a decade) and hospital joint ventures.[4] The unifying logic is the same: scale wins the commoditized, price-pressured core through lower unit cost and stronger payer contracts, squeezing the sub-scale independent. The difference is only how far along each is.

9. Risks

The level's risks, in brief (fuller version in the 62151 primer):

• Reimbursement / pricing power — the biggest risk. Neither labs nor imaging set most of their own prices; PAMA-driven CLFS cuts and MPFS erosion push routine prices structurally down.[3][4][12]
• Coverage lag and utilization controls — new tests can go unpaid for years; prior authorization delays scans.[3][4]
• Leverage — sharper in imaging — the debt-financed, capital-heavy roll-up model is fragile when volumes wobble (Akumin's 2023 bankruptcy is the cautionary case).[4]
• Labor — shortages of pathologists, radiologists, and technicians raise costs and cap throughput.
• Compliance, quality, and cybersecurity — complex multi-payer billing invites False Claims Act exposure, and both halves are standing data-breach targets.[3][4]
• Disclosure risk for private investors — most of imaging and much of the lab tail are private, and the federal data omit hospital and physician-office activity, adding an information gap to private diligence.

10. How to invest, and the outlook

Public-market route — mostly a bet on labs. The deepest public exposure to NAICS 6215 is the lab majors, Quest (DGX) and Labcorp (LH) — GDP-plus volume growth, real margins, dividends and buybacks (remembering Labcorp's ~22% biopharma/contract-research arm is not lab revenue).[5][6] For growth, the molecular/genomic testers offer 20–40% growth at higher valuation risk. Imaging's public menu is thin — RadNet (RDNT) and newly public Lumexa (LMRI).[4][7][8]

Private-market route — mostly a bet on imaging (and the lab tail). This is where most of the level actually sits for a direct investor: PE healthcare-services funds, roll-ups of independent imaging centers, hospital joint ventures, and the real estate under the centers; on the lab side, PE-backed regional platforms and physician-led pathology groups.[3][4][9]

Editorial judgment. NAICS 6215 is a defensive, demographically favored, consolidating industry whose ceiling is set less by demand than by what payers will pay. Because it is a single-child level, the full analysis — the lab-versus-imaging split that is the real story, the company map, and the detailed economics — lives in the 62151 primer; read it next. The durable winners share one trait: either genuine scale (lowest cost per test or scan) or a differentiated, well-reimbursed menu. For most public investors, "owning NAICS 6215" in practice means owning the lab giants; owning the imaging half means going private.

---

Sources

1. U.S. Census Bureau / NAICS, "2022 NAICS: 6215 Medical and Diagnostic Laboratories" and child code 62151 / grandchild codes 621511 / 621512 (definitions, inclusions, and excluded hospital/physician-office codes 622 and 6211). https://www.census.gov/naics/?input=6215&year=2022
2. Ingested ground-truth federal statistics for NAICS 6215 — U.S. Census Bureau 2022 Economic Census, Concentration of Largest Firms (receipts $81.1B; 9,154 firms; CR4 24.9%, CR8 29.9%, CR20 38.3%, CR50 49.6%; HHI suppressed) and County Business Patterns 2023 (23,603 establishments; 332,060 employees; $24.7B annual payroll; $6.35B first-quarter payroll).
3. Child/grandchild primer, NAICS 621511 — Medical Laboratories (U.S.) (receipts $56.1B; concentration CR4 36%; CLIA / CLFS / PAMA / LDT regulation; Quest and Labcorp as scale operators; specialty-tester cohort), as synthesized in the 62151 primer. Draws on 2022 Economic Census, 2023 County Business Patterns, and company disclosures cited therein.
4. Child/grandchild primer, NAICS 621512 — Diagnostic Imaging Centers (U.S.) (receipts $25.0B; concentration CR4 12.9% / HHI 76.1; PE and hospital-JV ownership; MPFS / IDTF / MIPPA / MQSA regulation; RadNet, Lumexa, Fonar; Akumin leverage case; site-of-service migration), as synthesized in the 62151 primer. Draws on 2022 Economic Census, 2023 County Business Patterns, and company/industry sources cited therein.
5. Quest Diagnostics Inc., "Fourth Quarter and Full Year 2025 Financial Results" and 2025 Form 10-K (FY2025 revenue ~$11.0B; requisition volume and revenue per requisition as core metrics), Feb 2026. https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm
6. Labcorp Holdings Inc., "2025 Fourth Quarter and Full Year Results" and 2025 Form 10-K (FY2025 revenue ~$13.95B; Diagnostics ~$10.9B / ~78%; biopharma ~22%), Feb 2026. https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm
7. RadNet, Inc., "Fourth Quarter 2025 Results and 2026 Guidance" and 2025 Form 10-K (FY2025 revenue ~$2.04B; ~418 centers; DeepHealth digital-health arm), 2026. https://www.sec.gov/Archives/edgar/data/790526/000162828026013337/rdnt-20251231.htm
8. Specialty / molecular / genomic testers, FY2025 results — Exact Sciences (EXAS), Natera (NTRA), Guardant Health (GH), NeoGenomics (NEO), Veracyte (VCYT), Fulgent Genetics (FLGT); as compiled in the 62151 / 621511 primers, Feb 2026.
9. U.S. Small Business Administration, Table of Small Business Size Standards (NAICS 621511 = $41.5M receipts; 621512 = $19.0M receipts), 2023. https://www.sba.gov/document/support-table-size-standards
10. U.S. Census Bureau, "County Business Patterns Methodology" and "2022 Economic Census Methodology" (CBP excludes self-employed, non-employer, and most government workers; Economic Census targets paid-employee establishments and generally excludes government-owned ones). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
11. Grand View Research / Mordor Intelligence / Fortune Business Insights, clinical-laboratory-services and diagnostic-imaging-services market sizing (total U.S. clinical-lab testing ~$80–90B+; hospital labs >50% of testing revenue; total imaging services in the hundreds of billions), 2025. https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-services-market
12. Centers for Medicare & Medicaid Services, "Clinical Laboratory Fee Schedule / PAMA Reporting Resources" (CLFS administered pricing; PAMA private-payer-median peg; CY2025 0% reduction; CAA 2026 delay; 15%/yr caps 2027–2029), 2025–2026. https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule/clfs-pama-reporting-resources
13. Centers for Medicare & Medicaid Services / Radiology Business, "Medicare Physician Fee Schedule 2025" (conversion factor −2.83%; ~10% erosion over a decade). https://info.hapusa.com/blog-0/medicare-finalizes-2025-fee-schedule-cut
14. U.S. Census Bureau, "Older Adults Outnumber Children in 11 States…" (61.2M / 18.0% aged 65+ in 2024) and American Society for Clinical Laboratory Science on the geriatric testing tailwind (nearly 1 in 5 aged 65+ by 2030), 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html